Skip to main content

Advertisement

SpringerLink
Log in

Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Identifying novel predictors of hematogenous metastasis is essential to select optimal therapeutic strategies for pancreatic cancer. The goal of this study was to clarify the clinical implications of p53 and platelet-derived growth factor receptor-β (PDGFR-β) in pancreatic cancer using immunohistochemistry (IHC).

Methods

Specimens obtained by surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS–FNA) of the primary tumor were used for IHC. EUS–FNA was performed before any treatment. We analyzed the clinical implications of p53 and PDGFR-β IHC. We also performed a comparative analysis of the IHC findings between surgical and EUS–FNA specimens.

Results

This study involved 149 patients (120 who did not receive and 29 who received preoperative therapy). EUS–FNA specimens were obtained from 20 patients without preoperative therapy and 20 patients with preoperative therapy. Abnormal p53 and high PDGFR-β expression was significantly correlated with a high incidence of hematogenous metastasis (p < 0.001) and poor postoperative survival (p = 0.006). In patients without preoperative therapy, the results for p53 and PDGFR-β staining were concordant between surgical and EUS–FNA specimens in 95 % of the cases. In patients with preoperative therapy, 80 and 70 % of the patients showed consistent p53 and PDGFR-β expression between surgical and EUS–FNA specimens, respectively.

Conclusions

Pancreatic cancer patients with simultaneous abnormal p53 and high PDGFR-β expression have a significantly higher risk of hematogenous metastasis and a poor prognosis after surgery. IHC evaluation using EUS–FNA specimens may be able to identify patients with highly metastatic pancreatic cancer who may benefit from aggressive therapeutic intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vincent A, Herman J, Schulick R et al (2011) Pancreatic cancer. Lancet 378:607–620

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ying JE, Zhu LM, Liu BX (2012) Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18:736–745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cameron JL, Riall TS, Coleman J et al (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yachida S, Iacobuzio-Donahue CA (2009) The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 133:413–422

    PubMed  Google Scholar 

  5. Rose JB, Rocha FG, Alseidi A et al (2014) Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 21:1530–1537

    Article  PubMed  Google Scholar 

  6. Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260

    Article  CAS  PubMed  Google Scholar 

  9. Obata A, Eura M, Sasaki J et al (2000) Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 89:187–193

    Article  CAS  PubMed  Google Scholar 

  10. Freed-Pastor WA, Mizuno H, Zhao X et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240

    Article  CAS  PubMed  Google Scholar 

  12. Oshima M, Okano K, Muraki S et al (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258:336–346

    Article  PubMed  Google Scholar 

  13. Shin SH, Kim SC, Hong SM et al (2013) Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 42:216–222

    Article  CAS  PubMed  Google Scholar 

  14. Kim H, Saka B, Knight S et al (2014) Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 20:1865–1872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nenutil R, Smardova J, Pavlova S et al (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259

    Article  CAS  PubMed  Google Scholar 

  16. Pietras K, Sjoblom T, Rubin K et al (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439–443

    Article  CAS  PubMed  Google Scholar 

  17. Cao R, Bjorndahl MA, Religa P et al (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6:333–345

    Article  CAS  PubMed  Google Scholar 

  18. Kodama M, Kitadai Y, Sumida T et al (2010) Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 101:1984–1989

    Article  CAS  PubMed  Google Scholar 

  19. Ehnman M, Missiaglia E, Folestad E et al (2013) Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 73:2139–2149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hwang RF, Yokoi K, Bucana CD et al (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534–6544

    CAS  PubMed  Google Scholar 

  21. Singh PK, Wen Y, Swanson BJ et al (2007) Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 67:5201–5210

    Article  CAS  PubMed  Google Scholar 

  22. Tsao AS, Wei W, Kuhn E et al (2011) Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-beta) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer 12:369–374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Weissmueller S, Manchado E, Saborowski M et al (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157:382–394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sobin LH, Gospodarowicz MK, Wittekind C et al (2010) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Hoboken

    Google Scholar 

  25. Juliachs M, Munoz C, Moutinho CA et al (2014) The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 20:658–667

    Article  CAS  PubMed  Google Scholar 

  26. Rhim AD, Mirek ET, Aiello NM et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chen H, Sun Y, Wu C et al (2012) Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 19:321–331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gao L, Antic T, Hyjek E et al (2013) Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma. Cancer Cytopathol 121:644–652

    Article  PubMed  Google Scholar 

  29. Boone BA, Sabbaghian S, Zenati M et al (2014) Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol 110:171–175

    Article  PubMed  Google Scholar 

  30. Higashi M, Yokoyama S, Yamamoto T et al (2015) Mucin Expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Pancreas 44:728–734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Preis M, Gardner TB, Gordon SR et al (2011) MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 17:5812–5821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Grand-in-Aid for Scientific Research (26462067) from the Japan Society for the Promotion of Science, Ministry of Health, Labour and Welfare, Japan.

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan

    Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda & Shoji Natsugoe

  2. Health Sciences, Graduate School of Medical Sciences, Kagoshima University, Kagoshima, Japan

    Hiroyuki Shinchi

Authors
  1. Hiroshi Kurahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kosei Maemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Mataki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiko Sakoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Shinchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoji Natsugoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kurahara.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurahara, H., Maemura, K., Mataki, Y. et al. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. World J Surg 40, 1977–1984 (2016). https://doi.org/10.1007/s00268-016-3477-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-016-3477-2

Keywords

Search

Navigation